Prediabetes in patients receiving tacrolimus in the first year after kidney transplantation: A prospective and multicenter study

Transplantation

Volumn 85, Issue 8, 2008, Pages 1133-1138

  Porrini, Esteban ^a   Moreno, Jose Manuel ^b   Osuna, Antonio ^b   Benitez, Rocio ^c   Lampreabe, Ildefonso ^c   Diaz, Juan Manuel ^d   Silva, Irene ^d   Domínguez, Rosa ^e   Gonzalez Cotorruelo, Julio ^e   Bayes, Beatriz ^f   Lauzurica, Ricardo ^f   Ibernon, Meritxell ^g   Moreso, Francisco ^g   Delgado, Patricia ^a   Torres, Armando ^a  

^a HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^c HOSPITAL DE CRUCES   (Spain)

^d FUNDACIÓ PUIGVERT   (Spain)

^e HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^f HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^g HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Insulin resistance; Prediabetes; Tacrolimus

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; BASILIXIMAB; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; DACLIZUMAB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BODY MASS; CLINICAL TRIAL; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG DOSE REDUCTION; FEMALE; GLUCOSE METABOLISM; GRAFT REJECTION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; KIDNEY GRAFT; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL GLUCOSE TOLERANCE TEST; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SINGLE DRUG DOSE;

ADULT; AGED; BODY MASS INDEX; CHOLESTEROL, HDL; DIABETES MELLITUS; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LOGISTIC MODELS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; TACROLIMUS; TRIGLYCERIDES;

EID: 42549109573     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31816b16bd     Document Type: Article

References (30)

1. Shapiro R, Young J, Milford E, et al. Immunosuppression: Evolution in practice and trends, 1993-2003. Am J Transplant 2005; 5: 874.
2. Boots J, Christiaans M, van Hooff J. Effect of immunosuppressive agents on long-term survival of renal transplant recipients: Focus on the cardiovascular risk. Drugs 2004; 64: 2047.
3. Markell M. New-onset diabetes mellitus in transplant patients: Pathogenesis, complications and management. Am J Kidney Dis 2004; 43: 953.
4. Heisel O, Heisel R, Balshaw R, et al. New onset diabetes mellitus in patients receiving calcineurin inhibitors: A systematic review and meta-analysis. Am J Transplant 2004; 4: 583.
5. Weir MR, Fink JC. Risk for posttransplant diabetes mellitus with current immunosuppressive medications. Am J Kidney Dis 1999; 34: 1.
6. Vincenti F, Friman S, Scheuermann E, et al. DIRECT (Diabetes Incidence after Renal Transplantation: Neoral C Monitoring Versus Tacrolimus) Investigators. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007; 6: 1506.
7. Miller J, Mendez R, Pirsch J, et al. For the FK/MMF dose-ranging kidney transplant study group. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. Transplantation 2000; 69: 875.
8. Maes B, Kuypers D, Messiaen T, et al. Posttransplantation diabetes mellitus in FK-506-treated renal transplant recipients: Analysis of incidence and risk factors. Transplantation 2001; 72: 1655.
9. David-Neto E, Lemos FC, Fadel LM, et al. The dynamics of glucose metabolism under calcineurin inhibitors in the first year after renal transplantation in nonobese patients. Transplantation 2007; 84: 50.
10. Cho YM, Park KS, Jung HS, et al. High incidence of tacrolimus-associated posttransplantation diabetes in the Korean renal allograft recipients according to American diabetes association criteria. Diabetes Care 2003; 26: 1123.
11. Nathan D, Davidson M, DeFronzo R, et al. Impaired fasting glucose and impaired glucose tolerance. Diabetes Care 2007; 30: 753.
12. Meigs J, Muller D, Nathan D, et al. The natural history of progression from normal glucose tolerance to type 2 diabetes in the Baltimore longitudinal study of aging. Diabetes 2003; 52: 1475.
13. Cosio F, Kudva Y, van der Velde M, et al. New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int 2005; 67: 2415.
14. Alvarez A, Fernández J, Porrini E, et al. Carotid atheromatosis in non-diabetic renal transplant recipients. The role of prediabetic glucose homeostasis alterations. Transplantation 2007; 84: 870.
15. Anonymous. Diagnosis and classification of diabetes mellitus. Diabetes Care 2005; 28: s37.
16. Davidson J, Wilkinson A, Dantal J, et al. New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Transplantation 2003; 75: SS3-24.
17. McLaughlin T, Reaven G, Abbasi F, et al. Is there a simple way to identify insulin-resistance individuals at increased risk of cardiovascular disease? Am J Cardiol 2005; 96: 399.
18. Mariat C, Alamartine E, Barthelemy JC, et al. Assessing renal graft function in clinical trials: Can tests predicting glomerular filtration rate substitute for a reference method? Kidney Int 2003; 65: 289.
19. Tamayo-Marco B, Faure-Nogueras E, Roche-Asensio M, et al. Prevalence of diabetes and impaired glucose tolerance in Aragón, Spain. Diabetes Care 1997; 20: 534.
20. Castell C, Tresserras R, Serra J, et al. Prevalence of diabetes in Catalonia (Spain): An oral glucosa tolerance test-based population study. Diabetes Res Clin Pract 1999; 43: 33.
21. Boronat M, Varillas V, Saavedra P, et al. Diabetes mellitus and impaired glucose regulation in the Canary Islands (Spain): Prevalence and associated factors in the adult population in Telde, Gran Canaria. Diabet Med 2005; 23: 148.
22. Crutchlow M, Bloom R. Transplant-associated hyperglycemia: A new look at an old problem. Clin J Am Soc Nephrol 2007; 2: 343.
23. Armstrong K, Prins J, Beller E, et al. Should an oral glucose tolerance test be performed routinely in all renal transplant recipients? Clin J Am Soc Nephrol 2006; 1: 100.
24. Sharif A, Moore RH, Baboolal K, et al. The use of oral glucose tolerance tests to risk stratify for new-onset diabetes after transplantation: An underdiagnosed phenomenon. Transplantation 2006; 82: 1667.
25. Oterdoom L, de Vries A, Gansevoort R, et al. Determinants of insulin resistance in renal transplant recipients. Transplantation 2007; 15: 29.
26. Porrini E, Diaz Gómes M, Alvarez A, et al. Glycated haemoglobin levels are related to chronic subclinical inflammation in renal transplant patients without pre-existing or new-onset diabetes. Nephrol Dial Transplant 2007; 22: 1994.
27. Bayes B, Granada ML, Pastor MC, et al. Obesity, adiponectin and inflammation as predictors of new-onset diabetes mellitus after kidney transplantation. Am J Transplant 2007; 7: 416.
28. Stumvoll M, Goldstein B, van Heften T. Type 2 diabetes: Principles of pathogenesis and therapy. Lancet 2005; 365: 1333.
29. Boots JM, van Duijnhoven EM, Christiaans MH, et al. Glucose metabolism in renal transplant recipients on tacrolimus: The effect of steroid withdrawal and tacrolimus trough level reduction. J Am Soc Nephrol 2002; 13: 221.
30. Rodrigo E, de Cos M, Sanchez B, et al. High initial blood levels of tacrolimus in overweight renal transplant recipients. Transplant Proc 2005; 37: 1453.